Privia Health Group, Inc. (PRVA) — Fair Value Analysis
Base-case fair value (P50): $3526.85 · Current price: $23.99 · Verdict: Undervalued
The Verdict on PRVA
Monte Carlo simulations suggest PRIVIA HEALTH GROUP INC (PRVA) is Deeply Undervalued based on its current trading price of $23.99. Our median fair value (P50) for PRVA stands at a substantial $3526.85, indicating a projected upside of +14601.3% from current levels. This significant disparity underscores a potential mispricing by the market, with the simulations modeling thousands of forward scenarios to arrive at this robust valuation. Investors assessing PRVA should consider the profound gap between its present market capitalization and its calculated intrinsic worth.
How PRVA stacks up against peers
When evaluating PRIVIA HEALTH GROUP INC's intrinsic value, it's important to consider its operational and financial health. While our Monte Carlo analysis reveals a strong undervaluation, PRVA's quality tier is rated as "average" relative to its sector peers. This average standing suggests that while the company's fundamentals support a much higher fair value of $3526.85, there isn't a premium associated with exceptional operational performance or financial strength compared to the broader market. The current price of $23.99 doesn't reflect the company's P50, indicating potential for re-rating regardless of its average quality tier.
What this means for investors
For investors, the massive +14601.3% upside from PRVA's current price of $23.99 to its median fair value of $3526.85 presents a compelling long-term opportunity. Despite an average quality tier, the Monte Carlo simulations consistently point to a significant undervaluation, suggesting the market may be overlooking core aspects of PRVA's future cash flows. A substantial upside scenario is implied by the data, though investors should also be aware of potential downside scenarios. To understand the full bear and bull case distribution, including P10 and P90 targets, and track PRVA's fair value as new fundamentals are released, sign up for FairCurve.
Frequently Asked Questions
Is PRVA overvalued or undervalued right now?
Based on our Monte Carlo simulations, PRIVIA HEALTH GROUP INC (PRVA) is deeply undervalued. Its current price of $23.99 is significantly below its median fair value (P50) of $3526.85.
What is the bear case and bull case for PRVA?
The full Monte Carlo distribution, including bear (P10) and bull (P90) targets, plus the probability of upside, is available with a free FairCurve account. We do not provide specific dollar values for these scenarios publicly.
How does FairCurve calculate PRVA's fair value?
FairCurve calculates PRVA's fair value using Monte Carlo simulations that model thousands of forward scenarios based on the company's fundamental drivers and historical performance to arrive at a robust valuation range.
How can I track PRVA's fair value as it changes?
You can add PRVA to a free FairCurve watchlist to receive daily fair-value updates and instant re-valuation when new earnings or significant fundamental data are released.